EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Multidisciplinary Management of Metabolic Dysfunction‐Associated Steatohepatitis: A Single‐Centre European Experience

Maria Antentas, Idoia Genua, Berta Ferández‐Camins, Elisabeth Pérez‐Chust, Francesca Mayolas‐Mateu, Eva Román, Maria Poca, German Soriano, Juan Antonio Arroyo‐Díaz, Marina Idalia Rojo‐López, Dídac Mauricio

Liver International Communications · 2026-03 · 7 (1)

DOI: 10.1002/lci2.70038 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Liver International Communications, online erschienen am 16.03.2026. Verfasst von Maria Antentas und 10 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Centro de Investigación Biomédica en Red Diabetes y Enfermedades Metabólicas Asociadas, Agència de Gestió d'Ajuts Universitaris i de Recerca, Fundación SEEN.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metabolic dysfunction‐associated steatotic liver disease (MASLD) can progress to steatohepatitis and fibrosis, often coexisting with obesity, type 2 diabetes, dyslipidaemia and hypertension. We evaluated the effectiveness of a one‐year, Mediterranean, hospital‐based lifestyle programme in patients with fibrotic steatohepatitis. Sixty‐two adults with liver stiffness ≥ F2 were enrolled and followed a personalised Mediterranean diet combined with physical activity counselling, with visits at baseline, 3, 6 and 12 months. Anthropometric, biochemical and clinical parameters were measured. Longitudinal changes were analysed using the Friedman test ( p < 0.05). The mean age was 63.5 years, and 46.8% were women. Comorbidities included hypertension (62.9%), dyslipidaemia (79.0%) and type 2 diabetes (T2D) (45.2%). After 6 and 12 months, significant improvements were observed in weight, body mass index, waist circumference, glycated haemoglobin, liver enzymes and liver stiffness. A coordinated, Mediterranean‐based lifestyle programme led to clinically meaningful improvements in hepatic and cardiometabolic outcomes in patients with fibrotic steatohepatitis.

Förderung

  • Centro de Investigación Biomédica en Red Diabetes y Enfermedades Metabólicas Asociadas
  • Agència de Gestió d'Ajuts Universitaris i de Recerca
  • Fundación SEEN
  • Instituto de Salud Carlos III
  • European Regional Development Fund
  • European Social Fund Plus

Zitieren

APA

Antentas, M., Genua, I., Ferández‐Camins, B., Pérez‐Chust, E., Mayolas‐Mateu, F., Román, E., Poca, M., Soriano, G., Arroyo‐Díaz, J. A., Rojo‐López, M. I., & Mauricio, D. (2026). Multidisciplinary Management of Metabolic Dysfunction‐Associated Steatohepatitis: A Single‐Centre European Experience. Liver International Communications, 7(1). https://doi.org/10.1002/lci2.70038

Vancouver

Antentas M, Genua I, Ferández‐Camins B, Pérez‐Chust E, Mayolas‐Mateu F, Román E, et al. Multidisciplinary Management of Metabolic Dysfunction‐Associated Steatohepatitis: A Single‐Centre European Experience. Liver International Communications. 2026;7(1). doi:10.1002/lci2.70038

BibTeX
@article{Antentas2026,
  author = {Antentas, Maria and Genua, Idoia and Ferández‐Camins, Berta and Pérez‐Chust, Elisabeth and Mayolas‐Mateu, Francesca and Román, Eva and Poca, Maria and Soriano, German and Arroyo‐Díaz, Juan Antonio and Rojo‐López, Marina Idalia and Mauricio, Dídac},
  title = {Multidisciplinary Management of Metabolic Dysfunction‐Associated Steatohepatitis: A Single‐Centre European Experience},
  journal = {Liver International Communications},
  year = {2026},
  volume = {7},
  number = {1},
  doi = {10.1002/lci2.70038}
}
Kostenlos starten →